Lantern Pharma CEO Details AI Platform's Role in Accelerating Cancer Drug Development

Lantern Pharma (NASDAQ: LTRN) is leveraging artificial intelligence to transform cancer drug development, with CEO Panna Sharma describing how the company's proprietary platform can compress development timelines and cost structures across oncology. In an interview recorded at the New York Stock Exchange, Sharma explained that Lantern's AI platform now self-learns, reads scientific papers, models molecules, predicts patient response, and suggests new indications for existing drugs.

The company's RADR platform processes over 200 billion oncology-focused data points using more than 200 machine learning algorithms to identify new therapies and reposition existing molecules. This AI-driven approach is particularly focused on high-unmet-need oncology indications where traditional drug development methods have struggled to deliver effective treatments efficiently. Sharma emphasized that this technology represents a fundamental shift in how cancer drugs are discovered and developed.

Lantern currently has three clinical-stage oncology candidates in development, including a Phase 2 trial targeting non-smoker non-small cell lung cancer and another program focused on cancers with DNA damage repair deficiency using synthetic lethality approaches. The company expects upcoming data milestones from its LP-184 program, which represents one of the most advanced candidates in their pipeline. Additional information about the company's development programs is available at https://ibn.fm/LTRN.

The broader implications of Lantern's approach extend beyond their own pipeline. The company plans to commercially roll out its AI platform to drug developers worldwide, potentially transforming how the entire pharmaceutical industry approaches oncology drug discovery. This could lead to more personalized treatments reaching patients faster and at lower costs, addressing one of the major challenges in modern healthcare.

Sharma envisions this technology helping to usher in what he calls a "golden era of medicine," where AI, data, and robotics work together to enable faster, cheaper, and more targeted cancer treatments. The interview with FintechTV provides additional context about how this technology is being implemented, accessible at https://ibn.fm/ZvbMK. The company estimates its AI-driven pipeline of innovative product candidates has a combined annual market potential exceeding $15 billion and could provide life-changing therapies to hundreds of thousands of cancer patients globally.

This development matters because traditional cancer drug development often takes over a decade and costs billions of dollars, with high failure rates. Lantern's AI approach could dramatically reduce both the time and financial barriers to bringing new cancer treatments to market, potentially making innovative therapies available to patients years sooner than through conventional methods. For the pharmaceutical industry, this represents a paradigm shift in research and development efficiency, while for cancer patients worldwide, it offers hope for more rapid access to targeted, effective treatments.